索拉非尼治疗国人晚期肝细胞癌的临床研究进展

原发性肝癌， 主要是肝细胞癌（HCC），是我国高发、常见的恶性肿瘤，晚期患者治疗棘手、预后恶劣。我国的HCC在发病原因、生物学行为、临床特征、治疗选择和预后上，都与西方国家明显不同，积极探索适合我国HCC患者合理规范的治疗具有重要意义。分子靶向药物索拉非尼作为口服多靶点多激酶抑制剂，经国际大型临床研究证实可以延长晚期HCC患者的生存期，在我国上市应用6年多，其疗效和安全性较好，但也存在一些问题。为了合理用药，进一步提高疗效，近年来，国内学者陆续开展了一系列索拉非尼单药、联合其他药物或手段治疗国人晚期HCC的临床研究和观察。本文拟对其相关研究进展进行综述和讨论，以提供临床参考。

Research progress on treatment of sorafenib for Chinese patients with advanced hepatocellular carcinoma

Primary liver cancer is a very common malignant tumor with especially higher incidence in China， very tough treatment and poor prognosis， which mainly consisted of hepatocellular carcinoma （HCC）. The pathogenesis， clinical features， biological behavior， prognosis and treatment selection in Chinese patients are markedly different from those patients in western countries. It is of great significance to explore reasonable treatment strategies of Chinese population. Sorafenib is an oral， multi-targeted， multi-kinase inhibitor， which has been proved to prolong the survival of patients with advanced HCC by large scale， international clinical studies. Sorafenib has been used in China for more than 6 years and demonstrated its good efficacy and safety. However， there are many shortcomings of it. Recently， the domestic scholars have carried out many clinical studies of sorafenib monotherapy and in combination with other drugs or methods to improve its efficacy. This paper comprehensively reviews current situation and progress of related studies.